These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8837983)

  • 1. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 7. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
    Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
    Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycine therapy of schizophrenia: some caveats.
    Waziri R
    Biol Psychiatry; 1996 Feb; 39(3):155-6. PubMed ID: 8837976
    [No Abstract]   [Full Text] [Related]  

  • 12. [Depressive symptoms in schizophrenia].
    Gerard A
    Encephale; 1998 Jul; 24 Spec No 1():24-6. PubMed ID: 9809250
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
    Strzelecki D; Kropiwnicki P; Rabe-Jabłońska J
    Psychiatr Pol; 2013; 47(4):609-20. PubMed ID: 24946468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics.
    Hicks PB; Vinogradov S; Riney SJ; Su K; Csernansky JG
    J Clin Psychopharmacol; 1989 Jun; 9(3):209-12. PubMed ID: 2567742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
    Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Silipo G; Lichtenstein M
    Arch Gen Psychiatry; 1999 Jan; 56(1):29-36. PubMed ID: 9892253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
    Tugg LA; Desai D; Prendergast P; Remington G; Reed K; Zipursky RB
    Schizophr Res; 1997 May; 25(1):71-8. PubMed ID: 9176929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.